Attention deficit hyperactivity disorder is a common neurodevelopmental disorder mainly affecting primary school aged children. There are usually one or more comorbid conditions that add to the child's functional impairment and affect their response to medication and psychosocial treatments. There is emerging evidence that children do better when medicines are given in conjunction with comprehensive behavioural interventions. The psychostimulants dexamphetamine and methylphenidate are the primary drug treatments for attention deficit hyperactivity disorder.
Introduction
Attention deficit hyperactivity disorder (ADHD) is characterised by developmentally inappropriate levels of inattention and hyperactivity/impulsiveness. It is associated with academic underachievement, social marginalisation, early schoolleaving and occupational underachievement. ADHD can have deleterious effects on adult personality formation and is a risk factor for a range of adult psychiatric disorders, alcohol and substance abuse and dependence disorders. 1 The two most common subtypes of ADHD are the combined type, where impairment is due to inattention and hyperactivity/ impulsiveness (also known as hyperkinetic disorder), and the inattentive type, where impairment is caused by inattention alone. About 3-5% of primary school aged children have ADHD at any one time, with approximately 1.5% having the combined type. The prevalence of ADHD reduces by approximately 50% every five years from childhood through adolescence into adulthood. Hence, there are a small group of adult ADHD patients who require ongoing comprehensive treatment.
Aetiology
The precise cause of ADHD remains unknown although there appear to be numerous risk factors that contribute to its onset. Key psychosocial risk factors, such as the quality of relationships in the family unit, school classroom and playground, are now considered to be non-specific maintaining (risk) or protective (resilience) factors, depending on their nature. 2 Dietary factors such as artificial food colourings and additives are now known to be non-specific risk factors of small effect in primary school aged children. Similarly, other environmental factors such as maternal smoking, exposure to toxic levels of lead, reduced iodine levels and early physical abuse or neglect exert non-specific effects that have remained hard to define.
Comorbid disorders
ADHD is rarely encountered as a 'pure', discrete disorder. 
Diagnosis
A comprehensive specialist clinical assessment is required to identify ADHD. This should include a patient history provided by multiple informants (parents, children, teachers and other responsible adults, siblings, peers with parental permission) and patient examination. Comorbid conditions such as learning disorders, hearing impairment, speech and language developmental delay and developmental coordination disorder need to be identified so they can be treated appropriately.
Treatment strategies
There is insufficient evidence to identify which child with ADHD will respond to psychosocial or drug treatments. All cases of ADHD should be initially treated with psychosocial interventions alone. This is usually sufficient for milder cases, while moderate to severe cases of ADHD need medication in conjunction with psychosocial interventions. Often psychiatric referral is indicated to optimise the complex mix of medication, targeted psychosocial and specific specialist services that are needed to maximise learning and development. 3, 4 These services include speech therapy for speech and language disorders, educational remediation for learning disorders, and occupational therapy for developmental coordination disorder.
At present, there is insufficient evidence to support targeted dietary adjustments or free fatty acid supplementation (for example, fish oils). 2, 4 
Psychosocial interventions
Appropriate psychosocial interventions include positive reinforcement of desired behaviours (including token systems), penalties for undesired behaviours, and contingency contracts for older children and adolescents. Learning techniques to selfmanage stress and group social skills training have also proven helpful. In contrast, other psychosocial treatment approaches such as psychodynamic therapies are ineffective, aside from improving a given child's or parents' level of satisfaction that something is being done. 2
Dexamphetamine and methylphenidate
The psychostimulants dexamphetamine and methylphenidate remain the primary effective drug treatments for ADHD. 2, 4 They do not differ in effectiveness or adverse effects, although individual patients may appear to respond better to one than to the other.
These drugs decrease ADHD symptoms, improve cognitive deficits (for example, attention, memory and working memory), decrease academic and social impairments due to ADHD, improve quality of life for children and their families, and increase adherence and learning from psychosocial interventions. These effects were evident in short-term (4-6 weeks) and long-term (1-2 years) controlled trials.
Psychostimulant medications are thought to work by increasing the functional activity of dopamine and noradrenaline through inhibiting their presynaptic uptake. These actions appear to facilitate compensatory brain neural networks that promote more situation-appropriate cognitions, emotions and behaviour in a child with ADHD. 5 The effects are dose-dependent for hyperactivity/impulsiveness, while, in a subgroup of children, attention and working memory improve at low doses but can become impaired at high doses. Before starting psychostimulant drug therapy, children with pre-existing heart disease, a strong family history of heart disease or current symptoms and signs suggesting heart disease, require ECG monitoring. 6 To assess for therapeutic and adverse effects in the early phase of treatment, children should be carefully monitored by their parent(s) for the first five days with weekly consultations by phone or in person. Dosing is usually optimised after 1-2 weeks, and then weekly to monthly face-to-face monitoring is 
Initiating and monitoring drug therapy

Stopping treatment
Psychostimulant treatment should be ceased if there is no beneficial effect at home or at school, unacceptable adverse effects emerge in the short-or long-term, or the legal guardian of the child requests a trial of an alternative treatment.
If psychostimulant medication is ceased, it should be withdrawn gradually decreasing by one tablet per day until finished for short-acting preparations, and by switching from a long-acting to an equivalent short-acting form and then decreasing gradually until finished. Children should be monitored carefully over the following 1-2 weeks for re-emerging ADHD symptoms.
Adult use
Occasionally, psychostimulant medication will need to be continued into adult life. The abuse potential of such drugs has been repeatedly noted in the media. Interestingly, the pharmacodynamic and pharmacokinetic properties of psychostimulant medication and methamphetamine (the illegal form of amphetamine) differ to the extent that psychostimulant medication has a much lower potential for abuse.
Adverse effects
Key adverse effects are all dose-dependent and can be managed 
Other medications
When psychostimulant medication is ineffective, has adverse effects such as emotional disturbance or worsening of tics, or is not a treatment option that a patient will use, alternative options can be considered. 2, 4 These involve additional types of medication or specific psychosocial interventions known to ameliorate ADHD symptoms when mastered and put into practice by children with ADHD and their families.
Atomoxetine
Atomoxetine is the current second-line treatment for ADHD. It is a potent reuptake inhibitor of noradrenaline at the presynaptic terminal and is of some benefit for children with ADHD in the short and long terms. It has a longer duration of action than psychostimulant medication and can be helpful during the evening and sleep as well as during the day. Its adverse effects profile is similar to psychostimulant medication. Initial insomnia, appetite suppression, irritability and nervousness are the most common adverse effects along with nausea and headache. There is a precaution in the product information that atomoxetine may increase the risk of suicidal ideation.
Imipramine
Imipramine, a tricyclic antidepressant, is a current third-line treatment for ADHD, although it is being virtually phased out of routine clinical practice. It is similar to atomoxetine although it has significant potential for cardiac adverse effects, mainly cardiac arrhythmias and/or conduction defects.
Clonidine
Clonidine, a central adrenergic agonist that reduces the presynaptic release of noradrenaline, is an alternative to imipramine. It can be used when other options are ineffective or contraindicated. Clonidine decreases the hyperactivity/ impulsiveness symptoms more than inattention at low doses, while there is some evidence of improved attention at higher doses.
Neuroleptic drugs
Atypical antipsychotics (for example, risperidone) and the sedative antipsychotics (for example, pericyazine) have limited benefit on core ADHD symptoms and unreliably improve cognition. However, they can be of benefit when there is severe co-occurring aggression or irritability/affective instability.
Specialist assessment is required before these medications are prescribed, given the potential for drug interactions and effects on the psychosocial treatments being applied.
Drug combinations
Every attempt should be made to use a single medication that maximises benefits and minimises adverse effects. However, combinations of medication are frequently required that target specific key symptoms associated with impairment, for example psychostimulants and clonidine to aid initial insomnia. Specialist advice is always recommended when drug combinations are used.
Conclusion
Developing an effective treatment plan for a child with ADHD involves careful and comprehensive assessment of information from the parents, child and teacher (with permission). Key comorbid conditions need to be identified and specific approved treatments applied for them. These treatments may require the management of ADHD to be modified.
The general practitioner has a central role in reviewing an agreed treatment plan and liaising with the paediatrician or psychiatrist to ensure adjustments are being made as each child with ADHD develops through adolescence into adulthood.
